Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

CVS quarterly profit beats; expects to close Aetna deal this month

Published 11/06/2018, 10:43 AM
Updated 11/06/2018, 10:43 AM
© Reuters. FILE PHOTO: Shoppers walk outside a CVS store and pharmacy in Medford

By Manas Mishra

(Reuters) - CVS Health Corp (N:CVS), which expects to close its $69 billion purchase of Aetna Inc (N:AET) this month, reported third-quarter profit that beat analysts' estimates on higher sales of prescription drugs.

Shares of the drugstore chain and pharmacy benefit manager (PBM) were up 2.7 percent at $75.70 in morning trading.

The company said it believes the Aetna deal will help it save more than $750 million in costs in the second year after it closes, as the combination reduces corporate expenses as well as produces "some" cuts in medical costs from decreased emergency room visits.

"The longer term medical cost savings will come from new programs that are only made possible through the combination and close integration of our two companies," Chief Executive Officer Larry Menlo said on call with analysts.

CVS, which last month won U.S. Department of Justice approval to buy Aetna, said it reached agreement with the state of California on the acquisition and expects to finalize terms over the coming days. The deal is expected to close before the Thanksgiving holiday, which falls on Nov. 22, CVS said.

The combination is expected to reshape the healthcare sector as it brings together one of the largest PBMs and one of the nation's oldest health insurers.

CVS could offer more preventive care services and screenings to Aetna customers in its clinics, such as enabling diabetes patients to monitor blood sugar levels, avoiding higher cost visits to doctors or emergency rooms.

Pharmacy same-store sales rose 8.7 percent in the quarter, while analysts were expecting a 7.7 percent rise.

Front end of the store same-store sales rose 0.8 percent versus analysts' expectations of an 0.8 percent drop, despite brick-and-mortar drugstore chains like CVS coming under increasing pressure from consumer shifts to online options.

Sales of beauty products at CVS stores have benefited from promotions and newer offerings. Last year, the company announced a initiative to offer over a hundred new South Korean beauty brands at its stores.

Excluding items, CVS Health said it earned $1.73 per share, topping analysts' average estimates by 2 cents.

Net revenue rose 2.4 percent to $47.27 billion, beating expectation of $47.18 billion.

Net income rose to $1.39 billion, or $1.36 per share, in the quarter. Its income tax provision declined by $268 million. (https://

© Reuters. FILE PHOTO: Shoppers walk outside a CVS store and pharmacy in Medford

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.